The Long Arm of Bionano Genomics Bionano’s
Post# of 99
(Total Views: 99)
Posted On: 09/08/2025 10:37:06 AM
The Long Arm of Bionano Genomics
Bionano’s deal with NVIDIA means its Saphyr system can be deployed in labs around the world without building massive data centers. By tapping NVIDIA’s RTX GPUs and AI software, any research or clinical lab, from a university in Germany to a biotech clinic in Brazil, can process huge Optical Genome Mapping data sets quickly and cost-effectively. This plug-and-play compute power removes a key barrier to adoption and lets partners in dozens of countries run end-to-end genome analysis on a standard lab bench or via the cloud.
Through its agreement with Revvity, Bionano’s CNV calling software is now bundled into newborn‐sequencing workflows sold in hospitals and research centers globally. Revvity’s established sales and support network in regions such as North America, Europe, and Asia-Pacific means that high-resolution genome mapping can be added to standard screening panels without any extra integration work. Newborn screening labs in dozens of countries can now spot structural variants that older methods miss, all because Bionano’s tools ride on top of Revvity’s existing instrumentation and service model.
Adding the NIH sole-source contract amplifies all of this on the world stage. When the U.S. National Institutes of Health locks in Bionano as its exclusive provider, it sends a powerful endorsement to research centers and health agencies everywhere. Publications and workflows coming out of NIH labs become templates that global peers trust, and other governments often follow NIH’s lead when setting procurement standards. That federal backing both cements Bionano’s reputation as the go-to OGM provider and raises a high barrier to competitors in public‐sector programs around the globe, fueling a steady wave of new partnerships, installations, and citations from top-tier institutes in more than 50 countries.
NVIDIA NVDA $169.47
Revvity RVTY $ 84.81
Bionano Genomics BNGO $ 4.25
Bionano’s deal with NVIDIA means its Saphyr system can be deployed in labs around the world without building massive data centers. By tapping NVIDIA’s RTX GPUs and AI software, any research or clinical lab, from a university in Germany to a biotech clinic in Brazil, can process huge Optical Genome Mapping data sets quickly and cost-effectively. This plug-and-play compute power removes a key barrier to adoption and lets partners in dozens of countries run end-to-end genome analysis on a standard lab bench or via the cloud.
Through its agreement with Revvity, Bionano’s CNV calling software is now bundled into newborn‐sequencing workflows sold in hospitals and research centers globally. Revvity’s established sales and support network in regions such as North America, Europe, and Asia-Pacific means that high-resolution genome mapping can be added to standard screening panels without any extra integration work. Newborn screening labs in dozens of countries can now spot structural variants that older methods miss, all because Bionano’s tools ride on top of Revvity’s existing instrumentation and service model.
Adding the NIH sole-source contract amplifies all of this on the world stage. When the U.S. National Institutes of Health locks in Bionano as its exclusive provider, it sends a powerful endorsement to research centers and health agencies everywhere. Publications and workflows coming out of NIH labs become templates that global peers trust, and other governments often follow NIH’s lead when setting procurement standards. That federal backing both cements Bionano’s reputation as the go-to OGM provider and raises a high barrier to competitors in public‐sector programs around the globe, fueling a steady wave of new partnerships, installations, and citations from top-tier institutes in more than 50 countries.
NVIDIA NVDA $169.47
Revvity RVTY $ 84.81
Bionano Genomics BNGO $ 4.25
(0)
(0)